Navigation Links
China Biopharma, Inc. Announces New Plan of Operation
Date:11/20/2007

HANGZHOU, China, Nov. 20 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) today announced its new plan of operation to take closer control and to better improve its current operation results. The company also plans to move away from the increasingly competitive and low margin vaccine business, and to enter new specialty pharmaceutical products.

"We plan to take more control on the available cash in out subsidiaries and move into higher market potential and higher margin specialty pharmaceutical products," says Peter Wang, CEO and Chairman of Board. "And we are negotiating with a few global vaccine manufacturers now for carrying their higher margin products, in order to avoid direct competitions with other manufacturers."

Recent changes in vaccine sectors have resulted in more vaccine manufacturers entering into low margin vaccine business such as flu vaccine, thus creating severe competition among, and squeezed profit margin of, vaccine distributors such as China Biopharma. Besides moving away from the low margin vaccine business, the company also starts to enter specialty pharmaceutical products such as the recently released anti-viral products.

China Biopharma has most of its operation in China. Working to take direct control on subsidiaries' operation and financial management, the company plans to increase its shareholding in China Zhejiang Tianyuan Biotech Co., Ltd., and eventually to have 100% control and ownership in this joint venture. With internally available resources, there would be no need to raise additional capital to complete the transactions. This is expected to improve current performance and increase operation stability.

"This new direction is expected to preserve available cash position and give us more operation flexibility," says Chunhui Shu, the new interim Chief Financial Officer. "In view of improvement and progress on our current operation results, we have made this plan to take more effective steps to strengthen our control over operating subsidiaries, preserve cash, apply available resources to, and refocus on higher margin, less competitive products with greater market potential."

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

CONTACT:

China Biopharma, Inc.

Tel: +1 (609) 651-8588

Attn. George Ji

ir@chinabiopharma.net

http://www.chinabiopharma.net


'/>"/>
SOURCE China Biopharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
Breaking Biology News(10 mins):